1. A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. Issue 9 (25th August 2016) Authors: Rovin, Brad H.; van Vollenhoven, Ronald F.; Aranow, Cynthia; Wagner, Carrie; Gordon, Robert; Zhuang, Yanli; Belkowski, Stanley; Hsu, Benjamin Journal: Arthritis & rheumatology Issue: Volume 68:Issue 9(2016) Page Start: 2174 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. Issue 9 (September 2016) Authors: Rovin, Brad H.; van Vollenhoven, Ronald F.; Aranow, Cynthia; Wagner, Carrie; Gordon, Robert; Zhuang, Yanli; Belkowski, Stanley; Hsu, Benjamin Journal: Arthritis & rheumatology Issue: Volume 68:Issue 9(2016) Page Start: 2174 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. Issue 6 (19th February 2013) Authors: Machado, Pedro; Landewé, Robert; Braun, Jürgen; Baraliakos, Xenofon; Hermann, Kay-Geert A; Hsu, Benjamin; Baker, Daniel; van der Heijde, Désirée Journal: Annals of the rheumatic diseases Issue: Volume 72:Issue 6(2013) Page Start: 1104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti–tumor necrosis factor antibody, in phase III clinical trials. Issue 2 (30th January 2013) Authors: Hsia, Elizabeth C.; Cush, John J.; Matteson, Eric L.; Beutler, Anna; Doyle, Mittie K.; Hsu, Benjamin; Xu, Stephen; Rahman, Mahboob U. Journal: Arthritis care & research Issue: Volume 65:Issue 2(2013:Feb.) Page Start: 309 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin‐6, in Patients With Moderately to Severely Active Rheumatoid Arthritis. (26th March 2018) Authors: Xu, Yan; Hu, Chuanpu; Zhuang, Yanli; Hsu, Benjamin; Xu, Zhenhua; Zhou, Honghui Journal: Journal of clinical pharmacology Issue: Volume 58:Number 7(2018) Page Start: 939 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. Issue 5 (26th February 2018) Authors: Taylor, Peter C; Schiff, Michael H; Wang, Qingmin; Jiang, Yusang; Zhuang, Yanli; Kurrasch, Regina; Daga, Shruti; Rao, Ravi; Tak, Paul P; Hsu, Benjamin Journal: Annals of the rheumatic diseases Issue: Volume 77:Issue 5(2018) Page Start: 658 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T). Issue 2 (4th March 2019) Authors: Tanaka, Yoshiya; Takeuchi, Tsutomu; Harigai, Masayoshi; Yamanaka, Hisashi; Nakano, Toshikazu; Akagi, Koshiro; Ukyo, Yoshifumi; Hsu, Benjamin Journal: Modern rheumatology Issue: Volume 29:Issue 2(2019) Page Start: 306 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study. Issue 6 (2nd November 2018) Authors: Takeuchi, Tsutomu; Tanaka, Yoshiya; Yamanaka, Hisashi; Harigai, Masayoshi; Nakano, Toshikazu; Akagi, Koshiro; Ukyo, Yoshifumi; Hsu, Benjamin Journal: Modern rheumatology Issue: Volume 28:Issue 6(2018) Page Start: 941 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Issue 10155 (13th October 2018) Authors: van Vollenhoven, Ronald F; Hahn, Bevra H; Tsokos, George C; Wagner, Carrie L; Lipsky, Peter; Touma, Zahi; Werth, Victoria P; Gordon, Robert M; Zhou, Bei; Hsu, Benjamin; Chevrier, Marc; Triebel, Manon; Jordan, Jarrat L; Rose, Shawn Journal: Lancet Issue: Volume 392:Issue 10155(2018) Page Start: 1330 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Exposure‐Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid Arthritis. (14th June 2018) Authors: Xu, Yan; Hu, Chuanpu; Zhuang, Yanli; Hsu, Benjamin; Xu, Zhenhua; Sharma, Amarnath; Zhou, Honghui Journal: Journal of clinical pharmacology Issue: Volume 58:Number 11(2018) Page Start: 1501 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗